|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore validate the anti-HCC effects of miR-212-3p through its ability to suppress CTGF and subsequent EMT.
|
31285444 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that curcumin may induce ROS scavenging by upregulating Nrf2 and GSH, thus inhibiting HIF-1<i>α</i> stabilization to suppress CTGF expression to exhibit its protection on HCC.
|
30800209 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCN2/MAPK/Id-1 loop feedback amplification is involved in oxaliplatin resistance, and the combination of oxaliplatin with inhibitor of CCN2 or MAPK signaling could provide a promising approach to ameliorating oxaliplatin resistance in HCC.
|
31250351 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of hepatocellular carcinoma tumorigenesis by curcumin may be associated with CDKN1A and CTGF.
|
29408622 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
S1P promotes YAP-mediated upregulation of cysteine-rich protein 61 and connective tissue growth factor (CTGF), and stimulates HCC cell proliferation.
|
29903770 |
2018 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of CTGF did not affect growth of PLC/PRF/5 cells, a hepatoma cell line with little CTGF expression, but facilitated their growth in the presence of LX-2 cells, an HSC line.
|
29967264 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting CTGF or CCL18 might provide beneficial effects for the clinical treatment of HCC.
|
28837877 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCN2 plays a promoting role in HCC progression through activating LRP6 in a HSPGs-dependent manner.
|
28870205 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results strongly suggest functional roles for CTGF-induced collagen I expression in formation of compact spheroids and in evading anticancer therapies in HCC, and suggest that losartan, administered in combination with conventional chemotherapy, might be an effective treatment for liver cancer.
|
28423507 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis determined that CTGF expression (HR 2.361; 95 % CI 1.195-4.665; p = 0.013) and vascular invasion (HR 2.367; 95 % CI 1.270-4.410; p = 0.007) were independent prognostic factors for recurrence of non-viral HCC.
|
26739296 |
2016 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Herein, we investigate whether miR-133b regulation of CTGF influences HCC cell proliferation and migration, and DR/OC response.
|
26945106 |
2016 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also observed a clear increase in CTGF mRNA and protein expression levels in HBV-positive HCC human tissue samples in comparison with the HBV-negative controls, indicating a possible negatively associated relationship between miR-18a and CTGF.
|
27421245 |
2016 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study is to determine the expression of CTGF and hypoxia inducible factors (HIF) in HCC and to clarify its impact on relapse and survival.
|
25847009 |
2015 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of intratumoral CTGF or IL-11 were independent prognostic factors for the development of BM in HCC patients.
|
23307318 |
2013 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Healthy individuals (n=56), as well as fibrotic (n=77), cirrhotic (n=17), and HCC-patients (n=72) with chronic hepatitis B (HBV) infection, clinically, biochemically and histopathologically well characterized and classified, were included for the measurements of CTGF-concentrations in serum using a newly developed CTGF-enzyme immunoassay.
|
23501329 |
2013 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, core protein increases and stabilizes β-catenin levels in hepatoma cell line Huh7 through inactivation of GSK-3β, which contributes to the up-regulation of downstream target genes, such as c-Myc, cyclin D1, WISP2 and CTGF.
|
22110662 |
2011 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CTGF was overexpressed 5-fold in 20 HCC tissues, compared with surrounding non-tumor liver tissue.
|
22340243 |
2011 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intratumoral CTGF expression combined with IL-11 expression may serve as a useful predictive biomarker for HCC BM.
|
21665914 |
2011 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
CTGF expression in HCC Edmondson's grade III-IV was significantly higher than that in HCC Edmondson's grade I-II (P = 0.022).
|
15526358 |
2004 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CTGF expression in HCC Edmondson's grade III-IV was significantly higher than that in HCC Edmondson's grade I-II (P = 0.022).
|
15526358 |
2004 |